New hope for tough leukemia: adding a pill to transplant prep
NCT ID NCT03247088
Summary
This study is testing if adding the drug sorafenib to standard chemotherapy drugs (busulfan and fludarabine) is safe and effective for adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The goal is to better prepare patients for a stem cell transplant from a donor. Researchers want to see if this combination helps control the cancer and improves survival after the transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.